$RLMD
RELMADA THERAPEUTICS, INC.

2024 Q4 Form 10-Q Financial Statement

#000121390024095398 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.86M
YoY Change -3.11%
% of Gross Profit
Research & Development $11.15M
YoY Change 6.65%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $23.01M
YoY Change 1.39%
Operating Profit -$23.01M
YoY Change 1.39%
Interest Expense $1.283M
YoY Change 85.92%
% of Operating Profit
Other Income/Expense, Net $1.283M
YoY Change 85.77%
Pretax Income -$21.73M
YoY Change -1.25%
Income Tax
% Of Pretax Income
Net Earnings -$21.73M
YoY Change -1.25%
Net Earnings / Revenue
Basic Earnings Per Share -$0.72
Diluted Earnings Per Share -$0.72
COMMON SHARES
Basic Shares Outstanding 30.17M shares 30.17M shares
Diluted Shares Outstanding 30.17M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $54.12M
YoY Change -49.09%
Cash & Equivalents $1.484M
Short-Term Investments $52.63M
Other Short-Term Assets $1.585M
YoY Change -43.4%
Inventory
Prepaid Expenses $1.585M
Receivables
Other Receivables
Total Short-Term Assets $55.70M
YoY Change -48.94%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $21.98K
YoY Change -53.95%
Total Long-Term Assets $21.98K
YoY Change -53.95%
TOTAL ASSETS
Total Short-Term Assets $55.70M
Total Long-Term Assets $21.98K
Total Assets $55.72M
YoY Change -48.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.346M
YoY Change -17.89%
Accrued Expenses $5.741M
YoY Change 3.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.087M
YoY Change -3.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $8.087M
Total Long-Term Liabilities $0.00
Total Liabilities $8.099M
YoY Change -3.58%
SHAREHOLDERS EQUITY
Retained Earnings -$622.2M
YoY Change 16.14%
Common Stock $30.17K
YoY Change 0.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $47.63M
YoY Change
Total Liabilities & Shareholders Equity $55.72M
YoY Change -48.95%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$21.73M
YoY Change -1.25%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$16.66M
YoY Change 43.22%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $16.14M
YoY Change 318.23%
Cash From Investing Activities $16.14M
YoY Change 318.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -89.60K
YoY Change
NET CHANGE
Cash From Operating Activities -16.66M
Cash From Investing Activities 16.14M
Cash From Financing Activities -89.60K
Net Change In Cash -602.5K
YoY Change -92.25%
FREE CASH FLOW
Cash From Operating Activities -$16.66M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
dei Entity File Number
EntityFileNumber
000-55347
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
RELMADA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-5401931
dei Entity Address Address Line1
EntityAddressAddressLine1
2222 Ponce de Leon
dei Entity Address Address Line2
EntityAddressAddressLine2
Floor 3
dei Entity Address City Or Town
EntityAddressCityOrTown
Coral Gables
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33134
dei City Area Code
CityAreaCode
(786)
dei Local Phone Number
LocalPhoneNumber
629-1376
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
RLMD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30174202 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1483789 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4091568 usd
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
52633938 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
92232292 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1584803 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1185057 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
55702530 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
97508917 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21975 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
43125 usd
CY2024Q3 us-gaap Assets
Assets
55724505 usd
CY2023Q4 us-gaap Assets
Assets
97552042 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2345541 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3506009 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5741220 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8688791 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8086761 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12194800 usd
CY2024Q3 us-gaap Program Rights Obligations Noncurrent
ProgramRightsObligationsNoncurrent
12562 usd
CY2024Q3 us-gaap Liabilities
Liabilities
8099323 usd
CY2023Q4 us-gaap Liabilities
Liabilities
12194800 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30174202 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30174202 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30099203 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30099203 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
30174 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
30099 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
669819907 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
646229824 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-622224899 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-560902681 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
47625182 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
85357242 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55724505 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
97552042 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11149136 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10454072 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35175531 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40055287 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11859702 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12238566 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29639951 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36817686 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
23008838 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
22692638 usd
us-gaap Operating Expenses
OperatingExpenses
64815482 usd
us-gaap Operating Expenses
OperatingExpenses
76872973 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23008838 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22692638 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-64815482 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-76872973 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
856478 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1321441 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
2875379 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
3892478 usd
CY2024Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
147835 usd
CY2023Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-51714 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
334082 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-718422 usd
CY2024Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
278555 usd
CY2023Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-579147 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
283803 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
72329 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1282868 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
690580 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3493264 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3246385 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-21725970 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-22002058 usd
us-gaap Net Income Loss
NetIncomeLoss
-61322218 usd
us-gaap Net Income Loss
NetIncomeLoss
-73626588 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.45
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30174202 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30174202 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30099203 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30099203 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30160242 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30160242 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30099203 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30099203 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
85357242 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
8295468 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
246747 usd
CY2024Q1 rlmd Adjustments To Additional Paid In Capital To Atm Fees
AdjustmentsToAdditionalPaidInCapitalToATMFees
-25000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-21828126 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
72046331 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
7213419 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-17768122 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
61491628 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
7949125 usd
CY2024Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
-89601 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-21725970 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
47625182 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
140436302 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
11354466 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-26321576 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
125469192 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
11169517 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-25302954 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
111335755 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
11392938 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-22002058 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
100726635 usd
us-gaap Net Income Loss
NetIncomeLoss
-61322218 usd
us-gaap Net Income Loss
NetIncomeLoss
-73626588 usd
us-gaap Share Based Compensation
ShareBasedCompensation
23458012 usd
us-gaap Share Based Compensation
ShareBasedCompensation
33916921 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
334082 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-718422 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
283803 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
72329 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-512432 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
378596 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1188309 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1160468 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2405184 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2947571 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1641475 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
12562 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42956164 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41409492 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
11424986 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
57151963 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
51641225 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
99864149 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
40216239 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
42712186 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
246747 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
-114601 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
132146 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2607779 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1302694 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4091568 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5395905 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1483789 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6698599 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 - BUSINESS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Relmada Therapeutics, Inc. (Relmada or the Company) (a Nevada corporation), is a clinical-stage, publicly traded biotechnology company focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. Relmada is also developing a proprietary, modified-release formulation of psilocybin (REL-P11) for metabolic indications.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable. The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with the Food and Drug Administration (FDA) and other governmental regulations and approval requirements.</p>
us-gaap Net Income Loss
NetIncomeLoss
-61322218 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42956164 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are stock-based compensation expenses and recorded amounts related to income taxes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1483789 usd
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
52633938 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
92232292 usd
CY2024Q3 us-gaap Lessee Finance Lease Remaining Lease Term
LesseeFinanceLeaseRemainingLeaseTerm
P12M
CY2024Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
147835 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
334082 usd
CY2024Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
278555 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
283803 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14716043 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15483009 shares
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
611200 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
365100 usd
CY2024Q3 rlmd Prepaid Research And Development
PrepaidResearchAndDevelopment
730300 usd
CY2023Q4 rlmd Prepaid Research And Development
PrepaidResearchAndDevelopment
695000 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
243300 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
125000 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1584800 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1185100 usd
CY2024Q3 rlmd Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
4042700 usd
CY2023Q4 rlmd Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
5394700 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
252300 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
174000 usd
CY2024Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
970500 usd
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2632400 usd
CY2024Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
395400 usd
CY2023Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
372200 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
80300 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
115500 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5741200 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8688800 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
110000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.13 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2024Q3 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
12562 usd
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
12562 usd
us-gaap Unrecognized Tax Benefits Income Tax Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
300000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P3Y9M29D
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
246747 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
100000000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.041 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0451 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.135 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.141 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
32000000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M10D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
17416192 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.99
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11183370 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
487434 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.1
rlmd Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P9Y7M17D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
74999 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
18407 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
4757628 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13052592 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.47
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
599973 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8888189 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.28
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M7D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
111698 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
900000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
3240 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23458000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
33916900 usd
rlmd Royalty Payments Percentage
RoyaltyPaymentsPercentage
0.02 pure
rlmd Royalties Received
RoyaltiesReceived
0.20 pure
rlmd Net Sales
NetSales
0.02 pure
us-gaap Payments For Fees
PaymentsForFees
45000 usd
rlmd Tiered Payments
TieredPayments
0.20 pure
us-gaap Taxes And Licenses
TaxesAndLicenses
45000 usd
CY2021Q3 us-gaap Entertainment License Agreement For Program Material Capitalized Cost
EntertainmentLicenseAgreementForProgramMaterialCapitalizedCost
12700000 usd
CY2021Q3 us-gaap Development In Process
DevelopmentInProcess
160000000 usd
CY2021Q3 us-gaap Payments For Rent
PaymentsForRent
11000 usd
CY2021Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5M
CY2021Q3 rlmd Lessee Operating Sublease Option To Expired
LesseeOperatingSubleaseOptionToExpired
2021-12-31
CY2023Q1 us-gaap Payments For Rent
PaymentsForRent
14500 usd
CY2023Q1 rlmd Lessee Operating Sublease Option To Expired
LesseeOperatingSubleaseOptionToExpired
2023-11-30
CY2023Q4 us-gaap Payments For Rent
PaymentsForRent
12000 usd
CY2023Q4 rlmd Lessee Operating Sublease Option To Expired
LesseeOperatingSubleaseOptionToExpired
2024-05-31
CY2024Q2 us-gaap Payments For Rent
PaymentsForRent
10500 usd
CY2024Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2025-05-30
us-gaap Operating Lease Expense
OperatingLeaseExpense
179700 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
213500 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
107300 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
118800 usd
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 rlmd Non Rule10b51 Arr Modified Flag
NonRule10b51ArrModifiedFlag
false
CY2024Q3 rlmd Rule10b51 Arr Modified Flag
Rule10b51ArrModifiedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
rlmd Share Based Compensation Arrangement By Share Basedd Payment Award Options Outstanding Granted Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBaseddPaymentAwardOptionsOutstandingGrantedAggregateIntrinsicValue
usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
rlmd Share Based Compensation Arrangement By Share Baseed Payment Award Options Outstanding Forfeited Intrinsic Value
ShareBasedCompensationArrangementByShareBaseedPaymentAwardOptionsOutstandingForfeitedIntrinsicValue
usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
rlmd Share Based Compensation Arrangement By Share Based Payment Award Options Outstandin Aggregate Intrinsic Value Cancelled
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandinAggregateIntrinsicValueCancelled
usd
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
3 usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001553643

Files In Submission

Name View Source Status
0001213900-24-095398-index-headers.html Edgar Link pending
0001213900-24-095398-index.html Edgar Link pending
0001213900-24-095398.txt Edgar Link pending
0001213900-24-095398-xbrl.zip Edgar Link pending
ea0217510-10q_relmada.htm Edgar Link pending
ea021751001ex31-1_relmada.htm Edgar Link pending
ea021751001ex31-2_relmada.htm Edgar Link pending
ea021751001ex32-1_relmada.htm Edgar Link pending
ea021751001ex32-2_relmada.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rlmd-20240930.xsd Edgar Link pending
rlmd-20240930_cal.xml Edgar Link unprocessable
ea0217510-10q_relmada_htm.xml Edgar Link completed
Show.js Edgar Link pending
rlmd-20240930_def.xml Edgar Link unprocessable
rlmd-20240930_lab.xml Edgar Link unprocessable
rlmd-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable